UroGen (NASDAQ:URGN) applauded BCAN's New Faces of Bladder Cancer report, a national survey of more than 1,100 patients highlighting recurrence burden and procedural load.
Key findings: nearly 80% fear recurrence (over 90% for patients under 50), women 86%, retained-bladder patients 87%, many report five or more cystoscopies and some report more than 15 procedures.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – URGN
-1.86%
-1.86%Session close to close
In the Mar 13 session, URGN declined 1.86%, reflecting a mild negative market reaction.
This announcement underscores the chronic, recurrent nature of bladder cancer, with fear of recurren...
Analysis
This announcement underscores the chronic, recurrent nature of bladder cancer, with fear of recurrence affecting up to 90% of younger patients and substantial cystoscopy burdens. It complements URGN’s focus on urothelial cancers highlighted in recent clinical and regulatory disclosures. Investors may track how such patient-reported data inform future trial design, quality-of-life endpoints, and physician adoption for therapies like ZUSDURI, alongside ongoing developments in URGN’s RTGel-based pipeline.
Key Figures
Survey sample size:more than 1,100 patientsFear of recurrence:nearly 80%Fear of recurrence (<50):more than 90%+5 more
8 metrics
Survey sample sizemore than 1,100 patientsNational BCAN bladder cancer patient survey
Fear of recurrencenearly 80%All survey respondents with bladder cancer
Fear of recurrence (<50)more than 90%Patients under 50 years old
Fear of recurrence (women)86%Female bladder cancer patients in survey
Fear of recurrence (bladder retained)87%Patients who retained their bladder
High cystoscopy burdenfive or more cystoscopiesSubstantial proportion of surveyed patients
Very high cystoscopy burdenmore than 15 proceduresSome surveyed bladder cancer patients
Initial diagnosis profile47% NMIBC, 23% CIS, 22% MIBCReported initial bladder cancer stage at diagnosis
Announced TD Cowen healthcare conference presentation and 1x1 investor meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has often been followed by modest or negative moves, with only the positive Phase 3 ZUSDURI data seeing a small gain.
Recent Company History
Over recent months, URGN has reported several notable developments. On Feb 27, positive ENVISION Phase 3 data for ZUSDURI in recurrent LG‑IR‑NMIBC corresponded with a +2.46% move. In contrast, the Mar 2 earnings release and related Pharmakon refinancing, which added access to up to $250M in term loans, saw shares fall about 12%. Subsequent conference participation and inducement RSU grants prompted only small negative reactions. Against this backdrop, the BCAN survey support is a non‑financial, advocacy-focused update.
Key Terms
cystoscopies, non-muscle invasive bladder cancer (NMIBC), carcinoma in situ (CIS), muscle-invasive disease (MIBC), +1 more
5 terms
cystoscopiesmedical
"Many respondents report undergoing five or more cystoscopies, with some experiencing..."
A cystoscopy is a medical exam where a thin, lighted tube with a camera is inserted through the urethra to look inside the bladder and urinary tract, similar to using a flashlight and camera to inspect the inside of a pipe. It matters to investors because the number of these exams, the devices and disposable tools used, reimbursement rates, and safety or regulatory developments directly affect revenues and costs for hospitals, clinics, and medical device companies tied to urology care.
non-muscle invasive bladder cancer (NMIBC)medical
"47% initially diagnosed with non-muscle invasive bladder cancer (NMIBC), 23% with..."
Non-muscle invasive bladder cancer (NMIBC) is a form of bladder cancer that is confined to the inner lining of the bladder and has not grown into the deeper muscle layer; think of it as a superficial patch on wallpaper rather than a stain that has soaked through the wall. It matters to investors because NMIBC often requires repeated treatments and monitoring, drives demand for outpatient therapies and diagnostics, and creates a sizable, ongoing market for drugs, devices, and procedures due to high recurrence and long-term care costs.
carcinoma in situ (CIS)medical
"47% initially diagnosed with non-muscle invasive bladder cancer (NMIBC), 23% with carcinoma in situ (CIS)..."
Carcinoma in situ (CIS) is a group of abnormal cells that look like cancer under a microscope but remain confined to the layer of tissue where they started and have not invaded nearby tissues or spread. Think of it as a small fire behind a closed window — serious because it can progress, but easier to contain than an active blaze. For investors, CIS matters because its detection, treatment options and regulatory pathways strongly influence demand for diagnostics, therapies and the commercial outlook for related medical products.
muscle-invasive disease (MIBC)medical
"23% with carcinoma in situ (CIS), and 22% with muscle-invasive disease (MIBC)..."
Muscle-invasive disease (MIBC) is a form of cancer—most commonly used for bladder cancer—where the tumor has grown from the organ’s surface into the underlying muscle layer, like roots pushing into soil rather than staying on the surface. It matters to investors because MIBC typically requires more aggressive treatments, has different clinical trial pathways and reimbursement considerations, and therefore influences the market size, development timelines and revenue potential for drugs, diagnostics and medical devices.
upper tract urothelial carcinomamedical
"smaller proportions reporting advanced, metastatic, or upper tract urothelial carcinoma."
A type of cancer that starts in the cells lining the upper urinary tract—the kidney’s urine-collecting area (renal pelvis) and the tube that carries urine to the bladder (ureter). It matters to investors because incidence, diagnostic rates, and the effectiveness or approval of new tests or treatments can change demand for drugs, devices, and services; think of it like a target market size and outcome that can move a company’s revenue and stock value.
National survey of more than 1,100 bladder cancer patients finds nearly 80% report fear of recurrence, rising above 90% among patients under 50
Many respondents report undergoing five or more cystoscopies, with some experiencing more than 15 procedures
PRINCETON, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a biotechnology company dedicated to developing innovative therapies for urothelial and specialty cancers, today commended the Bladder Cancer Advocacy Network (BCAN) on its release of The New Faces of Bladder Cancer Report, a national patient-reported survey underscoring the chronic and recurrent nature of bladder cancer.
The survey, which captures the experiences of more than 1,100 bladder cancer patients across the United States, found that nearly 80% of respondents reported fear of recurrence, rising to more than 90% among patients under 50. Among women, 86% reported fear of recurrence, and among patients who retained their bladder, 87% reported ongoing concern. The report also documents the cumulative procedural burden associated with bladder cancer management, with a substantial proportion of patients reporting five or more cystoscopies and some experiencing more than 15 procedures over the course of their disease.
“These findings reinforce what patients and clinicians experience every day — bladder cancer is often a chronic condition defined by recurrence, repeated procedures, and persistent uncertainty,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “When patients face years of surveillance and intervention, treatment discussions must consider not only tumor control but also long-term quality of life, personal priorities, and emotional burden. Elevating the patient voice through data of this scale is critical to improving care.”
Survey respondents represented diverse clinical experiences across all bladder cancer stages, including 47% initially diagnosed with non-muscle invasive bladder cancer (NMIBC), 23% with carcinoma in situ (CIS), and 22% with muscle-invasive disease (MIBC), with smaller proportions reporting advanced, metastatic, or upper tract urothelial carcinoma.
“This report reflects the real burden of living with bladder cancer and the lasting impact of recurrence,” said Meri-Margaret Deoudes, Chief Executive Officer of BCAN. “We thank UroGen for supporting this research, and for helping ensure that patient voices remain central to improving care.”
UroGen provided financial support for the survey and report. BCAN independently conducted the research and maintains full ownership and authorship of the findings.
About UroGen Pharma Ltd. UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product is approved to treat low-grade upper tract urothelial cancer, and our second product, is approved for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both products are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.UroGen.com to learn more or follow us on X, @UroGenPharma.
What did UroGen (URGN) say about BCAN's March 13, 2026 New Faces of Bladder Cancer report?
UroGen said the report underscores bladder cancer's recurrent, chronic nature and emotional burden for patients. According to UroGen, the survey of 1,100+ patients highlights repeated surveillance, procedural load, and the need to weigh quality of life in treatment discussions.
How common is fear of recurrence among bladder cancer patients in the BCAN report cited by UroGen (URGN)?
Nearly 80% of respondents reported fear of recurrence, rising above 90% for patients under 50. According to UroGen, the findings show pronounced anxiety across subgroups, including women (86%) and retained-bladder patients (87%).
What procedural burden does the BCAN survey report that UroGen (URGN) highlighted on March 13, 2026?
Many patients reported undergoing five or more cystoscopies, with some experiencing more than 15 procedures. According to UroGen, the survey documents cumulative surveillance and intervention burden across disease courses.
What patient populations and stages were represented in the BCAN survey UroGen (URGN) referenced?
Respondents included diverse clinical stages: 47% initially diagnosed with NMIBC, 23% with CIS, and 22% with MIBC. According to UroGen, smaller proportions reported advanced, metastatic, or upper tract urothelial carcinoma.
Did UroGen (URGN) fund the BCAN New Faces of Bladder Cancer report and who authored it?
UroGen provided financial support for the survey, while BCAN independently conducted and retains full ownership and authorship of the findings. According to UroGen, BCAN led research design and reporting.
How might the BCAN report highlighted by UroGen (URGN) influence treatment discussions for bladder cancer?
The report suggests treatment discussions should weigh tumor control alongside long-term quality of life and emotional burden. According to UroGen, patient-centered data of this scale supports integrating surveillance impact into care planning.
